“VONJO has addressed a significant unmet need in cytopenic MF patients and has seen an incredible uptake in its first year on the market,” said Behzad Khosrowshahi, Chief Executive Officer of the Trust. “We are excited to purchase a second royalty on this long duration, high-quality asset. This is the second royalty acquisition our team has completed in the past month and is a testament to our team’s ability to execute on our unique pipeline opportunities. With this transaction, DRI Healthcare has now deployed US$636 million with an additional US$59 million in potential milestone payments since our IPO. With a pipeline of over US$2.5 billion in high-quality assets, we are confident in our ability to reach our deployment target of US$850-900 million by the end of 2025 and to continue to generate value for our unitholders.”
